# A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer

> **NCT00683475** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 138 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** IMC-A12
- **DRUG:** Mitoxantrone
- **DRUG:** Prednisone
- **BIOLOGICAL:** IMC-1121B (ramucirumab)

## Key facts

- **NCT ID:** NCT00683475
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 138 (ACTUAL)
- **Last updated:** 2014-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00683475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00683475, "A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT00683475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*